Hypertension, Proteinuria, and Antagonism of Vascular Endothelial Growth Factor Signaling: Clinical Toxicity, Therapeutic Target, or Novel Biomarker?

This publication has 25 references indexed in Scilit:

• Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
  Journal of Clinical Oncology, 2007
• Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
  New England Journal of Medicine, 2007
• The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review
  European Journal Of Cancer, 2006
• Bevacizumab in the Treatment of Metastatic Colorectal Cancer: Safety Profile and Management of Adverse Events
  Seminars in Oncology, 2006
• Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis
  Kidney International, 2006
• Phase II Study of Neoadjuvant Chemotherapy and Radiation Therapy in the Management of High-Risk, High-Grade, Soft Tissue Sarcomas of the Extremities and Body Wall: Radiation Therapy Oncology Group Trial 9514
  Journal of Clinical Oncology, 2006
• Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
  Journal of Clinical Oncology, 2006
• Hypertension Management in Adults With Diabetes
  Diabetes Care, 2004
• Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
  JAMA, 2002
• Effects of Vascular Endothelial Growth Factor on Hemodynamics and Cardiac Performance
  Journal of Cardiovascular Pharmacology, 1996